Cancer research communications

· 11 papers in corpus
2026
doi:10.1158/2767-9764.crc-26-0163 ·PMID:41996637

Cancer is associated with many preexisting health conditions (PHC); however, accurately quantifying these links remains challenging. Although some studies have examined these associations, large-scale analyses using diverse electronic healt…

2025
doi:10.1158/2767-9764.crc-25-0147 ·PMID:40981433

Endometrioid and mucinous ovarian carcinomas represent nearly a fifth of ovarian cancers, but their molecular characteristics and pathologic origins are poorly understood. To identify the genomic and epigenomic alterations characteristic of…

2025
doi:10.1158/2767-9764.crc-25-0024 ·PMID:40459063

There are currently no effective treatments available for clear cell ovarian cancer (CCC). In this study, we aimed to identify effective drugs for CCC through high-throughput drug screening (HTDS) using ovarian cancer organoids and determin…

2025
doi:10.1158/2767-9764.crc-25-0140 ·PMID:40801326

Ovarian cancer is the fifth leading cause of cancer-related deaths among women. Most patients are diagnosed at late stage (III/IV), resulting in a 5-year survival rate below 30%. This is driven by the presentation of vague abdominal symptom…

2024
doi:10.1158/2767-9764.crc-23-0327 ·PMID:38197671

The biomarker CA125, a peptide epitope located in several tandem repeats of the mucin MUC16, is the gold standard for monitoring regression and recurrence of high-grade serous ovarian cancer in response to therapy. However, the CA125 epitop…

2024
doi:10.1158/2767-9764.crc-23-0275 ·PMID:38112643

Wnt ligand WNT4 is critical in female reproductive tissue development, with WNT4 dysregulation linked to related pathologies including breast cancer (invasive lobular carcinoma, ILC) and gynecologic cancers. WNT4 signaling in these contexts…

2023
doi:10.1158/2767-9764.crc-23-0138 ·PMID:37712874

Ovarian cancer has a poor prognosis and is difficult to detect in early stages. Therefore, developing new diagnostic markers for early-stage ovarian cancer is critical. Here, we developed a diagnostic marker for early-stage ovarian cancer o…

2023
doi:10.1158/2767-9764.crc-22-0410 ·PMID:36968229

The effect of risk factors on ovarian cancer differs by histotype, and the prevalence of such risk factors varies by race/ethnicity. It is not clear how ovarian cancer incidence has changed over time by histotype and race/ethnicity. We used…

2022
doi:10.1158/2767-9764.crc-22-0122 ·PMID:36082022

Targeting glutamine metabolism has emerged as a novel therapeutic strategy for several human cancers, including ovarian cancer. The primary target of this approach is the kidney isoform of glutaminase, glutaminase 1 (GLS1), a key enzyme in …

2022
doi:10.1158/2767-9764.crc-22-0075 ·PMID:35928983

The human microbiome has been strongly correlated with disease pathology and outcomes, yet remains relatively underexplored in patients with malignant endometrial disease. In this study, vaginal microbiome samples were prospectively collect…

2022
doi:10.1158/2767-9764.crc-22-0314 ·PMID:36311816

Current screening methods for ovarian cancer (OC) have failed to demonstrate a significant reduction in mortality. Uterine lavage combined with TP53 ultra-deep sequencing for the detection of disseminated OC cells has emerged as a promising…